IN THE SPOTLIGHT

Crizotinib Falls Short on DFS and OS Improvements in ALK+ NSCLC; When compared with observation, adjuvant crizotinib did not improve disease-free survival or overall survival...

Crizotinib Falls Short on DFS and OS Improvements in ALK+ NSCLC; When compared with observation, adjuvant crizotinib did not improve disease-free survival or overall survival...

Exploring Tailored Sequencing Strategies to Extend Survival in ALK-Positive Advanced NSCLC

Exploring Tailored Sequencing Strategies to Extend Survival in ALK-Positive Advanced NSCLC

BMS-986504 demonstrates durable responses in MTAP-deleted NSCLC, including EGFR and ALK-positive tumors

BMS-986504 demonstrates durable responses in MTAP-deleted NSCLC, including EGFR and ALK-positive tumors

BRIGHTSTAR Evaluates Local Consolidative Therapy Plus Brigatinib for ALK-Rearranged NSCLC

BRIGHTSTAR Evaluates Local Consolidative Therapy Plus Brigatinib for ALK-Rearranged NSCLC

BMS-986504 demonstrates durable responses in MTAP-deleted NSCLC, including EGFR and ALK-positive tumors

BMS-986504 demonstrates durable responses in MTAP-deleted NSCLC, including EGFR and ALK-positive tumors

BMS-986504 Shows Lasting Efficacy in MTAP-Deleted NSCLC, Targeting EGFR and ALK-Positive Tumors

BMS-986504 Shows Lasting Efficacy in MTAP-Deleted NSCLC, Targeting EGFR and ALK-Positive Tumors

BMS-986504 demonstrates durable responses in MTAP-deleted NSCLC, including EGFR and ALK-positive tumors

BMS-986504 demonstrates durable responses in MTAP-deleted NSCLC, including EGFR and ALK-positive tumors

BMS-986504 demonstrates durable responses in MTAP-deleted NSCLC, including EGFR and ALK-positive tumors

BMS-986504 demonstrates durable responses in MTAP-deleted NSCLC, including EGFR and ALK-positive tumors

Observation Outperforms Adjuvant Crizotinib for Resected ALK-Positive NSCLC

Observation Outperforms Adjuvant Crizotinib for Resected ALK-Positive NSCLC

BMS-986504 demonstrates durable responses in MTAP-deleted NSCLC, including EGFR and ALK-positive tumors

BMS-986504 demonstrates durable responses in MTAP-deleted NSCLC, including EGFR and ALK-positive tumors

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.